Bafna Pharmaceuticals has narrowed its March 2013 quarter standalone net loss to Rs 0.66 crore compared with Rs 2.08 crore net loss in the same period a year ago.
Total income from operations, on a standalone basis, rose to Rs 46.80 crore in the fourth quarter of 2012-13 fiscal compared with Rs 32.73 crore in the same quarter last fiscal.
The company’s board has recommended a final dividend of Re 0.60 per equity share for the financial year ended March 31, 2013.
Besides, the board has also approved the re-appointment of Bafna Mahaveer Chand as its Chairman and Managing Director and Paras Bafna as Whole Time Director.
For the financial year ended March 2013, the company’s consolidated net profit stood at Rs 4.01 crore against Rs 1.90 crore registered during the preceding fiscal.
Consolidated total income from operations stood at Rs 175.77 crore (Rs 128.63 crore).
Shares of the company closed at Rs 37.40 apiece, down 1.58 per cent over the previous close on the BSE.